News Breaks |
|
|
| September 13, 2012 |
| 07:25 EDT |  | ONCY | Oncolytics Biotech price target lowered to $5 from $7 at RBC Capital
RBC Capital reduced its target on Oncolytics after the company reported inconclusive data for its head and neck cancer treatment. The firm doesn't expect the next Phase III trial of the treatment to start until mid-2013, but it maintains an Outperform rating on the stock and plans to follow up with management. |
|
|
News For ONCY From The Last 14 Days Check below for free stories on ONCY the last two weeks. |
|
|
| There are no results for ONCY |
|
|
|
|
